Nuclide Therapeutics
Nuclide Therapeutics develops next-generation radioligand therapies combining therapeutic radionuclides with high-affinity targeting ligands to precisely target tumour cells.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Daily News – 22 September 2025
Listen to the episodeAbout Nuclide Therapeutics
Nuclide Therapeutics is a British oncology startup founded in 2024 developing next-generation radioligand therapy. RLT therapies combine radioactive radionuclides with high-affinity tumour targeting molecules delivering radiation directly to cancer cells. In September 2025 it raised GBP 5M in a seed round.
Market & Clients
Key Customers
Oncologists, specialist hospitals and the UK NHS; partnerships with CROs and radionuclide manufacturers.
Geographic Presence
Funding & Investors
Funding Rounds
- 2025 - Seed: euro5M
Similar Startups
Ternary Therapeutics
Biotech company using synthetic biology to develop therapies for serious diseases with innovative treatment approaches.
Read AnalysisSTORM Therapeutics
Biotech company developing targeted therapies using proprietary cell-targeting technology.
Read AnalysisBioOrbit
BioOrbit is a British startup that raised £9.8M seed in 2026 to manufacture cancer drugs in space. It develops an autonomous unit called BOX that uses microgravity to crystallize anti-cancer antibodies in purer form, potentially enabling subcutaneous administration formulations.
Read Analysis